Free Trial
NASDAQ:PRPH

ProPhase Labs (PRPH) Stock Price, News & Analysis

ProPhase Labs logo
$0.36 +0.02 (+5.91%)
As of 12:22 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About ProPhase Labs Stock (NASDAQ:PRPH)

Key Stats

Today's Range
$0.33
$0.36
50-Day Range
$0.24
$0.59
52-Week Range
$0.22
$5.62
Volume
84,634 shs
Average Volume
2.63 million shs
Market Capitalization
$14.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

ProPhase Labs Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
18th Percentile Overall Score

PRPH MarketRank™: 

ProPhase Labs scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for ProPhase Labs.

  • Earnings Growth

    Earnings for ProPhase Labs are expected to grow in the coming year, from ($1.27) to ($0.56) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ProPhase Labs is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ProPhase Labs is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    ProPhase Labs has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about ProPhase Labs' valuation and earnings.
  • Percentage of Shares Shorted

    6.29% of the float of ProPhase Labs has been sold short.
  • Short Interest Ratio / Days to Cover

    ProPhase Labs has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ProPhase Labs has recently increased by 49.99%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    ProPhase Labs does not currently pay a dividend.

  • Dividend Growth

    ProPhase Labs does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.29% of the float of ProPhase Labs has been sold short.
  • Short Interest Ratio / Days to Cover

    ProPhase Labs has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ProPhase Labs has recently increased by 49.99%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    ProPhase Labs has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.
  • Search Interest

    Only 1 people have searched for PRPH on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added ProPhase Labs to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ProPhase Labs insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    20.70% of the stock of ProPhase Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 9.45% of the stock of ProPhase Labs is held by institutions.

  • Read more about ProPhase Labs' insider trading history.
Receive PRPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProPhase Labs and its competitors with MarketBeat's FREE daily newsletter.

PRPH Stock News Headlines

Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…
ProPhase Labs reports FY24 EPS ($2.61) vs (98c) last year
ProPhase Labs FY 2024 Earnings Preview
See More Headlines

PRPH Stock Analysis - Frequently Asked Questions

ProPhase Labs' stock was trading at $0.7571 at the beginning of 2025. Since then, PRPH stock has decreased by 53.5% and is now trading at $0.3520.
View the best growth stocks for 2025 here
.

ProPhase Labs, Inc. (NASDAQ:PRPH) issued its quarterly earnings results on Thursday, May, 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.21. The company earned $3.63 million during the quarter, compared to analyst estimates of $9.86 million. ProPhase Labs had a negative net margin of 217.64% and a negative trailing twelve-month return on equity of 62.92%.
Read the conference call transcript
.

ProPhase Labs' top institutional shareholders include Chapin Davis Inc. (0.19%).
View institutional ownership trends
.

Shares of PRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ProPhase Labs investors own include Meta Platforms (META), Pfizer (PFE), Valero Energy (VLO), CymaBay Therapeutics (CBAY), Catalyst Pharmaceuticals (CPRX) and Energy Transfer (ET).

Company Calendar

Last Earnings
5/09/2024
Today
4/24/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PRPH
Employees
130
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-16,780,000.00
Net Margins
-217.64%
Pretax Margin
-298.21%

Debt

Sales & Book Value

Annual Sales
$6.77 million
Price / Cash Flow
N/A
Book Value
$2.74 per share
Price / Book
0.12

Miscellaneous

Free Float
18,932,000
Market Cap
$14.04 million
Optionable
Optionable
Beta
-0.56

Social Links


This page (NASDAQ:PRPH) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners